Synagis Infusion

Palivizumab
100mg
ABBVIE S.r.l
Pack size 1 Vial (Dry)
Dispensing mode POM
Source ITALY
AgentCITY MEDICAL STORE
Retail Price 4359.50 AED

Available as:

Indications

Synagis Infusion is used for: Indicated for the prevention of serious, lower respiratory tract disease, caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, Passive immunisation of infants against, lower respiratory tract infections

Adult Dose

Not indicated

Child Dose

Intramuscular Child: RSV Prophylaxis Indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease 15 mg/kg IM q1Month during RSV season with first dose administered prior to the season

Renal Dose

Administration

Contra Indications

Hypersensitivity to palivizumab or other humanised monoclonal antibodies.

Precautions

Patient w/ thrombocytopenia or other coagulation disorder, moderate to severe acute infection or febrile illness. Not intended for use in adult. Pregnancy and lactation.

Pregnancy-Lactation

Pregnancy Not indicated for use in females of reproductive potential Lactation Not indicated for use in females of reproductive potential Lactation: no studies done

Interactions

Adverse Effects

Side effects of Palivizumab : >10% Fever (27%) Rash (26%) 1-10% Antibody formation (1-2%) <1% Pain Hernia SGOT increased Cough Bronchiolitis Pneumonia Dyspnea Sinusitis Apnea Thrombocytopenia Failure to thrive Diarrhea Vomiting Conjunctivitis Eczema Anemia Angioedema Flu syndrome

Mechanism of Action

Palivizumab is a recombinant humanised monoclonal antibody which targets the surface glycoprotein, responsible for recognition and entry into the cell on the resp syncytial virus (RSV).

Note

Synagis 100mg Infusion manufactured by ABBVIE S.r.l. Its generic name is Palivizumab. Synagis is availble in United Arab Emirates. Farmaco UAE drug index information on Synagis Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Palivizumab :